Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis
出版年份 2017 全文链接
标题
Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis
作者
关键词
-
出版物
PHARMACOECONOMICS
Volume 35, Issue 8, Pages 845-858
出版商
Springer Nature
发表日期
2017-07-31
DOI
10.1007/s40273-017-0519-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation
- (2016) Marlise R. Luskin et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Clinical utility of next-generation sequencing in the diagnosis of hereditary haemolytic anaemias
- (2016) Archana M. Agarwal et al. BRITISH JOURNAL OF HAEMATOLOGY
- A novel 33-Gene targeted resequencing panel provides accurate, clinical-grade diagnosis and improves patient management for rare inherited anaemias
- (2016) Noémi B. A. Roy et al. BRITISH JOURNAL OF HAEMATOLOGY
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses
- (2016) Gillian D. Sanders et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
- (2016) Colin C. Pritchard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs
- (2016) Katarzyna Kolasa et al. Orphanet Journal of Rare Diseases
- Economic Burden and Quality-of-Life Effects of Chronic Lymphocytic Leukemia: A Systematic Review of the Literature
- (2016) Simon Frey et al. PHARMACOECONOMICS
- Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations
- (2016) Cynthia P. Iglesias et al. PHARMACOECONOMICS
- Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
- (2015) J. C. Byrd et al. BLOOD
- Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial
- (2015) Mohammed Z H Farooqui et al. LANCET ONCOLOGY
- Precision Medicine — Personalized, Problematic, and Promising
- (2015) J. Larry Jameson et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response
- (2015) Himisha Beltran et al. JAMA Oncology
- Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
- (2014) S. Stilgenbauer et al. BLOOD
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- How to Estimate Productivity Costs in Economic Evaluations
- (2014) Marieke Krol et al. PHARMACOECONOMICS
- Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework
- (2014) Mike Paulden et al. PHARMACOECONOMICS
- SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage
- (2013) R. Clifford et al. BLOOD
- Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
- (2013) Susan O'Brien et al. LANCET ONCOLOGY
- Cost of illness and economic burden of chronic lymphocytic leukemia
- (2013) Carl Rudolf Blankart et al. Orphanet Journal of Rare Diseases
- Clinical application of targeted and genome-wide technologies: can we predict treatment responses in chronic lymphocytic leukemia?
- (2013) Reem Alsolami et al. Personalized Medicine
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement
- (2013) Don Husereau et al. PHARMACOECONOMICS
- Issues surrounding the health economic evaluation of genomic technologies
- (2013) James Buchanan et al. PHARMACOGENOMICS
- High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations
- (2012) J. Edelmann et al. BLOOD
- UPDATE OF THE DUTCH MANUAL FOR COSTING IN ECONOMIC EVALUATIONS
- (2012) Siok Swan Tan et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia
- (2012) S J L Knight et al. LEUKEMIA
- ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia
- (2012) S Pospisilova et al. LEUKEMIA
- Clonal diversity analysis using SNP microarray: a new prognostic tool for chronic lymphocytic leukemia
- (2012) Linsheng Zhang et al. Cancer Genetics
- Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia
- (2011) P. Ouillette et al. BLOOD
- Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study
- (2010) Kathleen M Beusterien et al. Health and Quality of Life Outcomes
- TP53Mutation and Survival in Chronic Lymphocytic Leukemia
- (2010) Thorsten Zenz et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage
- (2009) J. Malcikova et al. BLOOD
- Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial
- (2009) T. Zenz et al. BLOOD
- Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up
- (2008) T. Zenz et al. BLOOD
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
- (2008) M. Hallek et al. BLOOD
- Whole-Genome Scanning by Array Comparative Genomic Hybridization as a Clinical Tool for Risk Assessment in Chronic Lymphocytic Leukemia
- (2008) Shelly R. Gunn et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- The impact of next-generation sequencing technology on genetics
- (2008) Elaine R. Mardis TRENDS IN GENETICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now